First Pacific Advisors, LP recently added 214,705 shares of
Bio-Rad Laboratories ($BIO) to their portfolio. This move comes amid suggestions of the company being undervalued due to a stock price drop and low debt. The company's projected Q1 2025 earnings release is expected to deliver key metrics and growth updates against a backdrop of stocks slump, a worrying trend that has seen shares slide by 28%. Amid these developments,
Bio-Rad Laboratories remains a favorite amongst institutional investors, with Revised Price Targets by Citigroup and a steady business stake in Sartorius, which drives its long-term value. Despite Q4 earnings and revenue not meeting expectations, and a revisal of the 2025 financial projections following Q1 reports, several analysts still hold positive outlooks for the company. Unfortunately, Bio-Rad's earnings have declined due to the weak academic research market. The company's acquisition offer for
Stilla is a potential upside. Bio-Rad's stock has recently hit a 52-week low. A key influencer of Bio-Rad's market shifts is macroeconomic concerns. Nevertheless, the company's potential is believed to still be under-realized due to uncertainties and a conservative management style.
Bio-Rad Laboratories Stocks News Analytics from Mon, 07 Mar 2022 08:00:00 GMT to Sat, 10 May 2025 22:26:00 GMT -
Rating 2
- Innovation 5
- Information 8
- Rumor -6
